TY - JOUR
T1 - Secondary Laparoscopic Cytoreduction in Recurrent Ovarian Cancer: A Large, Single-Institution Experience
AU - Gallotta, Valerio
AU - Conte, Carmine
AU - Giudice, Maria Teresa
AU - Nero, Camilla
AU - Vizzielli, Giuseppe
AU - Gueli Alletti, Salvatore
AU - Cianci, Stefano
AU - Lodoli, Claudio
AU - Di Giorgio, Andrea
AU - De Rose, Agostino Maria
AU - Fagotti, Anna
AU - Scambia, Giovanni
AU - Ferrandina, Maria Gabriella
PY - 2017
Y1 - 2017
N2 - Study Objective: To analyze the feasibility and safety of laparoscopic secondary cytoreductive surgery in a retrospective series of patients with platinum-sensitive recurrent ovarian cancer. Design: Retrospective cohort study (Canadian Task Force classification II-2). Setting: Catholic University of the Sacred Heart, Rome, Italy. Patients: Between October 2010 and October 2016, 58 patients with recurrent ovarian cancer were selected for a retrospective analysis of data. Interventions: All patients underwent a laparoscopic secondary cytoreduction with single or multiple procedures. Results: The most frequent pattern of recurrence was peritoneal (48.3%); 6 patients (10.3%) experienced parenchymal disease (spleen, n = 5; liver, n = 1), and 24 patients (41.4%) had lymph node recurrence. Complete debulking was achieved in all patients. The median operative time was 204 minutes (range, 55-448 minutes), median estimated blood loss was 70 mL (range, 20-300 mL), and the median length of hospital stay was 4 days (range, 1-21 days). Four patients (6.8%) experienced intraoperative complications. Early postoperative complications were documented in 6 patients (10.3%), but only 1 G3 complication was noted. The median duration of follow-up since secondary cytoreduction was 24 months (range, 9-71 months). Twenty-one patients (36.2%) experienced a second disease relapse. The median progression-free survival (PFS) was 28 months, and the 2-year PFS was 58.7%. Five patients died (8.6%); the 2-year overall survival was 90.7%. Conclusions: For selected patients, laparoscopy is a feasible and safe approach to optimal cytoreduction for patients with recurrent ovarian cancer.
AB - Study Objective: To analyze the feasibility and safety of laparoscopic secondary cytoreductive surgery in a retrospective series of patients with platinum-sensitive recurrent ovarian cancer. Design: Retrospective cohort study (Canadian Task Force classification II-2). Setting: Catholic University of the Sacred Heart, Rome, Italy. Patients: Between October 2010 and October 2016, 58 patients with recurrent ovarian cancer were selected for a retrospective analysis of data. Interventions: All patients underwent a laparoscopic secondary cytoreduction with single or multiple procedures. Results: The most frequent pattern of recurrence was peritoneal (48.3%); 6 patients (10.3%) experienced parenchymal disease (spleen, n = 5; liver, n = 1), and 24 patients (41.4%) had lymph node recurrence. Complete debulking was achieved in all patients. The median operative time was 204 minutes (range, 55-448 minutes), median estimated blood loss was 70 mL (range, 20-300 mL), and the median length of hospital stay was 4 days (range, 1-21 days). Four patients (6.8%) experienced intraoperative complications. Early postoperative complications were documented in 6 patients (10.3%), but only 1 G3 complication was noted. The median duration of follow-up since secondary cytoreduction was 24 months (range, 9-71 months). Twenty-one patients (36.2%) experienced a second disease relapse. The median progression-free survival (PFS) was 28 months, and the 2-year PFS was 58.7%. Five patients died (8.6%); the 2-year overall survival was 90.7%. Conclusions: For selected patients, laparoscopy is a feasible and safe approach to optimal cytoreduction for patients with recurrent ovarian cancer.
KW - Laparoscopy
KW - Obstetrics and Gynecology
KW - Recurrent ovarian cancer
KW - Secondary cytoreduction
KW - Laparoscopy
KW - Obstetrics and Gynecology
KW - Recurrent ovarian cancer
KW - Secondary cytoreduction
UR - http://hdl.handle.net/10807/112320
UR - http://www.elsevier.com/wps/find/journaldescription.cws_home/704371/description#description
U2 - 10.1016/j.jmig.2017.10.024
DO - 10.1016/j.jmig.2017.10.024
M3 - Article
SN - 1553-4650
SP - 31260
EP - 31268
JO - Journal of Minimally Invasive Gynecology
JF - Journal of Minimally Invasive Gynecology
ER -